These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 24289901

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. New and emerging treatments for advanced prostate cancer.
    George DJ, Kantoff PW, Lin DW.
    Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
    Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.
    Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
    Zustovich F, Fabiani F.
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
    [Abstract] [Full Text] [Related]

  • 9. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 10. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 11. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M.
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer.
    Small EJ, Penson DF, Sartor O.
    Clin Adv Hematol Oncol; 2011 Jul; 9(7 Suppl 13):1-15. PubMed ID: 22361784
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
    Saad F, Miller K.
    Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
    [Abstract] [Full Text] [Related]

  • 20. Abiraterone acetate for the treatment of prostate cancer.
    Ryan CJ, Cheng ML.
    Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.